Skip to main content

Table 2 Assessment of clinicopathological parameters predicting progression-free survival on univariate and multivariate analyses

From: Abundance of mitochondrial superoxide dismutase is a negative predictive biomarker for endometriosis-associated ovarian cancers

    PFS univariate PFS multivariate
   n HR (95% CI) p value HR (95% CI) p value
Age 60</≤60 11/50 0.4890 (0.105–2.289) 0.3632   
FIGO class III, IV/I, II 10/51 30.303 (7.353–125) < 0.0001 19.608 (5.952–66.667) < 0.0001
Blood marker Positive/negative 48/13 0.806 (0.204–3.185) 0.7583   
Histology Clear cell/endometrioid 41/20 2.212 (0.5778–8.475) 0.2463   
Standard treatment Incomplete/complete 8/53 6.410 (1.488–27.778) 0.0126 7.576 (1.828–31.25) 0.0052
SOD2 expression High/low 46/15 17.543 (1.825–166.667) 0.0130 10 (1.271–76.923) 0.0287
  1. On univariate analysis, high expression of mitochondrial superoxide dismutase (SOD2), incompleteness of standard treatment, and high International Federation of Gynecology and Obstetrics (FIGO) stage were associated with poor prognosis. Multivariate Cox proportional hazards analysis also confirmed that high SOD2 expression, incompleteness of standard treatment, and high FIGO stage were significant prognostic factors for worse progression-free survival (PFS). CI confidence interval, HR hazards ratio